Aktienanalyse zu Quanterix Corp (QTRX)QTRXQuanterix Corp

Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Quanterix Corp is not a good buy right now. The current price is $2.81, significantly below the analyst target of $3, indicating limited upside potential. The company has reported a year-to-date change of -56.30% and a gross margin of only 38.52% in Q2 2026, highlighting ongoing financial struggles. Additionally, the RSI of 37.18 suggests the stock is oversold, but the overall trend remains negative. The main risk is the lowered revenue guidance for 2026, now projected between $142 million and $148 million, down from $169 million to $174 million, indicating persistent market challenges.

4 analysts cover QTRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.50.